Aptorum Group Ltd
APM
Company Profile
Business description
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Contact
17 Hanover Square
LondonW1S 1BN
GBRT: +44 2080929299
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,330.97 | 16.23 | -0.19% |
| DAX 40 | 25,286.24 | 134.42 | -0.53% |
| Dow JONES (US) | 48,991.38 | 200.61 | -0.41% |
| FTSE 100 | 10,184.35 | 47.00 | 0.46% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,361.44 | 348.43 | -1.47% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,898.86 | 64.88 | -0.93% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |